(1)Whether, with regard to university system and partnerships with Multinational Pharma groups and COVID-19 and that the Ministerial Advisory Committee has leading academics conducting trials with global multinational corporations (MNCs), there is a framework when Higher Education is publicly funded to engage with global corporations; if not, what is the position in this regard; if so, will he furnish Ms H Ismail with the framework;
(2) what is the breakdown of the funding allocation for the trials led by Government and MNCs;
(3) whether (a) Astra Zeneca and (b) Johnson and Johnson pay our university system or patent knowledge?